

FLUIDIGM CORP

Form 3

February 10, 2011

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

EDB Investments Pte Ltd.

(Last)

(First)

(Middle)

20 BIOPOLIS WAY #09-01,

(Street)

CENTROS, U0A 138668

(City)

(State)

(Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

02/09/2011

3. Issuer Name **and** Ticker or Trading Symbol
FLUIDIGM CORP [FLDM]4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer ____ Other
(give title below) (specify below)5. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group

Filing(Check Applicable Line)

____ Form filed by One Reporting
Person_X_ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)Date Expir
Exercisable Date3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)Title Amount or
Number of
Shares4. Conversion
or Exercise
Price of
Derivative
Security5. Ownership
Form of
Derivative
Security:
Direct (D)
or Indirect
(I)
(Instr. 5)6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: FLUIDIGM CORP - Form 3

Series E Preferred Warrant (Right to Buy)	Â (1)	Â (2)	Common Stock	43,853 ⁽¹⁾ (5)	\$ 24.22	D (3) (4)	Â
Series E Preferred Stock	Â (1)	Â (6)	Common Stock	1,047,955 (1) (5)	\$ 0	D (3) (4)	Â
Series D Preferred Stock	Â (7)	Â (7)	Common Stock	623,531 ⁽⁵⁾ (7)	\$ 0	D (3) (4)	Â
Series C Preferred Stock	Â (7)	Â (7)	Common Stock	128,025 ⁽⁵⁾ (7)	\$ 0	D (4) (8)	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
EDB Investments Pte Ltd. 20 BIOPOLIS WAY #09-01 CENTROS,Â U0Â 138668	Â	Â X	Â	Â
Biomedical Sciences Investment Fund Pte Ltd. 20 BIOPOLIS WAY #09-01 CENTROS,Â U0Â 138668	Â	Â X	Â	Â
SINGAPORE BIO INNOVATIONS PTE LTD 250, NORTH BRIDGE ROAD #20-02 RAFFLES CITY TOWER SINGAPORE,Â U0Â 179101	Â	Â X	Â	Â

Signatures

Matthew
McCardell 02/10/2011

__Signature of
Reporting Person Date

Matthew
McCardell 02/10/2011

__Signature of
Reporting Person Date

Matthew
McCardell 02/10/2011

__Signature of
Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects the automatic conversion of each share of Series E Preferred Stock into 1.3 shares of Common Stock to occur upon the closing of the Issuer's initial public offering.
- (2) Expires immediately prior to the closing of the Issuer's initial public offering.
- (3) Biomedical Sciences Investment Fund Pte Ltd is the record holder of the securities reported on Lines 1, 2 and 3 of Table 2.

Edgar Filing: FLUIDIGM CORP - Form 3

- EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and
- (4) dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, one of the Issuer's directors, is a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
- (5) Reflects a 1-for-1.73 reverse stock split of the Issuer's outstanding shares effected on February 3, 2011.
- (6) Each share has no expiration date.
- (7) Reflects the automatic conversion of each share of Series C Preferred Stock and Series D Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering. Each share has no expiration date.
- (8) Singapore Bio-Innovations Pte Ltd is the record holder of the securities reported on Line 4 of Table 2.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.